Data from Development of an Anti-CD99 Antibody Enables Targeting of Diffuse Midline Glioma
View Full Paper
Ask AI
Bookmark
Share
Key Points
Targeting CD99 with the anti-CD99 antibody 10D1 reduces tumor growth in K27M+ diffuse midline glioma, indicating a promising therapeutic avenue.
Evaluation of 10D1 showed significant suppression of DMG growth in both in vitro and in vivo models, showcasing its potential efficacy.
The development strategy involved a chimeric antibody designed to induce apoptosis, highlighting a novel means of addressing treatment resistance in DMGs.
These findings underscore the need for clinical trials using the anti-CD99 antibody 10D1 in pediatric brain cancer therapies.
Discussion
No takes yet. Share an insight, caveat, or question.
Implication
This study demonstrates that targeting CD99 improves outcomes in K27M+ diffuse midline glioma, suggesting new therapeutic approaches for children.